Dilek Celebi, Hilal Akalin, Mustafa Tugrul Yilmaz, Munis Dundar
Abstract Climate change has imposed a significant struggle for survival most of the Earth’s species, highlighting the urgent need for a healthy and secure environment. Recent scientific investigations have primarily concentrated on the development and use of microorganisms as powerful biotechnological tools to address the escalating pollution that poses a severe threat to life. But this microorganisims long-term effects on biodiversity and ecosystems remain a subject of inquiry. In this comprehensive review, we aim to thoroughly evaluate the effects of microorganisms on the general ecosystem and critically assess the use of existing biotechnological tools developed to combat climate-related challenges. By shedding light on the potential implications, this review strives to contribute to a deeper understanding of the intricate interplay between microorganisms, ecosystems, and climate change mitigation.
{"title":"Impacts of Biotechnologically Developed Microorganisms on Ecosystems","authors":"Dilek Celebi, Hilal Akalin, Mustafa Tugrul Yilmaz, Munis Dundar","doi":"10.2478/ebtj-2023-0015","DOIUrl":"https://doi.org/10.2478/ebtj-2023-0015","url":null,"abstract":"Abstract Climate change has imposed a significant struggle for survival most of the Earth’s species, highlighting the urgent need for a healthy and secure environment. Recent scientific investigations have primarily concentrated on the development and use of microorganisms as powerful biotechnological tools to address the escalating pollution that poses a severe threat to life. But this microorganisims long-term effects on biodiversity and ecosystems remain a subject of inquiry. In this comprehensive review, we aim to thoroughly evaluate the effects of microorganisms on the general ecosystem and critically assess the use of existing biotechnological tools developed to combat climate-related challenges. By shedding light on the potential implications, this review strives to contribute to a deeper understanding of the intricate interplay between microorganisms, ecosystems, and climate change mitigation.","PeriodicalId":22379,"journal":{"name":"The EuroBiotech Journal","volume":"33 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135708021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Abstract Bioactive peptides are protein components which are inactive within the protein structure, and upon release by enzymatic hydrolysis, they exhibit special physiological functions. In the last years, the characteristics of bioactive peptides obtained from various plant, animal and microbial sources have received much attention. Bioactive peptides are produced using hydrolysis by enzymes extracted from plants or microorganisms, or digestive enzymes and fermentation by proteolytic starter cultures. The composition and sequence of the amino acids determines their different functions, including relaxing effects, solute binding properties, strengthening of the immune system, antioxidant, anti-microbial, anti-inflammatory, cholesterol-lowering and anti-hypertensive effects. Bioactive peptides are identified by different methods including membrane separation techniques and chromatography from protein hydrolysis products and using spectrometric techniques. The possibility of using bioactive peptides as health or therapeutic components depends on ensuring their bio stability, bioavailability and safety.
{"title":"Bioactive peptides: a review","authors":"Maghsoud Besharati, Maximilian Lackner","doi":"10.2478/ebtj-2023-0013","DOIUrl":"https://doi.org/10.2478/ebtj-2023-0013","url":null,"abstract":"Abstract Bioactive peptides are protein components which are inactive within the protein structure, and upon release by enzymatic hydrolysis, they exhibit special physiological functions. In the last years, the characteristics of bioactive peptides obtained from various plant, animal and microbial sources have received much attention. Bioactive peptides are produced using hydrolysis by enzymes extracted from plants or microorganisms, or digestive enzymes and fermentation by proteolytic starter cultures. The composition and sequence of the amino acids determines their different functions, including relaxing effects, solute binding properties, strengthening of the immune system, antioxidant, anti-microbial, anti-inflammatory, cholesterol-lowering and anti-hypertensive effects. Bioactive peptides are identified by different methods including membrane separation techniques and chromatography from protein hydrolysis products and using spectrometric techniques. The possibility of using bioactive peptides as health or therapeutic components depends on ensuring their bio stability, bioavailability and safety.","PeriodicalId":22379,"journal":{"name":"The EuroBiotech Journal","volume":"74 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135708180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Veronica Casali, Ingrid Clerc Guithon, Boudewijn van der Sanden, Olivier Stephan, Laetitia Gredy, Isabelle Vilgrain, Donald K Martin
Abstract An increasingly relevant functional measurement is a liquid biopsy to assist in the diagnosis of cancers. The existing approach for liquid biopsy is to utilize microfluidic chips for the isolation of circulating tumor cells (CTCs) or exosomes or extracellular vesicles (EV) from patient samples, and then for the analysis of the cargo contained inside the CTCs, exosomes or EVs. However, such an analysis does not provide a real-time liquid biopsy, since there is a long delay between the time of sample collection and the results from the analysis. Microfluidic chip-formats also provide the capability to mimic tissue functions from the analysis of small numbers of cells cultured in the chip. Analysis of the secreted molecules from such cells could provide a measurement of the secretome, which could be analogous to a liquid biopsy. A 3D structural organization of cells in microfluidic chips is usually in the form of organoids or spheroids. The analysis of organoids or spheroids is well-adapted for immunohistochemistry or ELISA-type identification of surface markers, but not for real-time analysis of secreted molecules since the fluid and molecules in the interior volume of the organoid or spheroid is not accessible in real-time. We have recently proposed an alternative novel design for a microfluidic chip format comprising 3D micro-niches that provide a real-time analysis of secretions produced directly from small numbers of cells. The microfluidic chip with 3D micro-niches then analyses the secretions from these monolayers in real-time (“secretome”). The microfluidic chip includes electronic biosensors that provide real-time measurement of secreted molecules. This short review concludes with a proposition for the means to utilize this novel microfluidic chip to function as a real-time and quantifiable diagnostic screening device to differentiate cancerous cells from healthy cells.
{"title":"Is a real-time quantifiable liquid biopsy achievable using a microfluidic lab-on-chip ?","authors":"Veronica Casali, Ingrid Clerc Guithon, Boudewijn van der Sanden, Olivier Stephan, Laetitia Gredy, Isabelle Vilgrain, Donald K Martin","doi":"10.2478/ebtj-2023-0014","DOIUrl":"https://doi.org/10.2478/ebtj-2023-0014","url":null,"abstract":"Abstract An increasingly relevant functional measurement is a liquid biopsy to assist in the diagnosis of cancers. The existing approach for liquid biopsy is to utilize microfluidic chips for the isolation of circulating tumor cells (CTCs) or exosomes or extracellular vesicles (EV) from patient samples, and then for the analysis of the cargo contained inside the CTCs, exosomes or EVs. However, such an analysis does not provide a real-time liquid biopsy, since there is a long delay between the time of sample collection and the results from the analysis. Microfluidic chip-formats also provide the capability to mimic tissue functions from the analysis of small numbers of cells cultured in the chip. Analysis of the secreted molecules from such cells could provide a measurement of the secretome, which could be analogous to a liquid biopsy. A 3D structural organization of cells in microfluidic chips is usually in the form of organoids or spheroids. The analysis of organoids or spheroids is well-adapted for immunohistochemistry or ELISA-type identification of surface markers, but not for real-time analysis of secreted molecules since the fluid and molecules in the interior volume of the organoid or spheroid is not accessible in real-time. We have recently proposed an alternative novel design for a microfluidic chip format comprising 3D micro-niches that provide a real-time analysis of secretions produced directly from small numbers of cells. The microfluidic chip with 3D micro-niches then analyses the secretions from these monolayers in real-time (“secretome”). The microfluidic chip includes electronic biosensors that provide real-time measurement of secreted molecules. This short review concludes with a proposition for the means to utilize this novel microfluidic chip to function as a real-time and quantifiable diagnostic screening device to differentiate cancerous cells from healthy cells.","PeriodicalId":22379,"journal":{"name":"The EuroBiotech Journal","volume":"207 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135707860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Abstract Obsessive-Compulsive Disorder (OCD) is a psychiatric illness that produces significant psychological distress in patients. Individuals with OCD have recurring unwanted thoughts or sensations which make them obsessed with something and feel to do something repetitively as a compulsion. In general detection of OCD is performed by symptoms analysis. However, the symptoms are significantly visible at a later stage. Even individuals with OCD have less faith in the analysis of the symptoms as long as it is not affecting their life negatively. As a result, they start their treatment at a later stage and the treatment process becomes longer. However, it is observed that if the detection is performed through laboratory analysis through some biomarkers then the patients have more faith in the detection process and can start their treatment well in advance. Therefore laboratory detection of OCD can play a vital role in OCD treatment effectiveness. Most of the laboratory detection process proposed in the literature uses Machine Learning on related biomarkers. However, the prediction accuracy rate is not enough. This research aims to analyze the approaches to pediatric OCD based on machine learning using neuroimaging biomarkers and oxidative stress biomarkers. The challenges in OCD detection and prediction using neuroimaging biomarkers, oxidative stress biomarkers, and Machine Learning models have been described. Further, it analyzes the performance of different machine learning models that were used for OCD detection and highlights the research gap to improve prediction accuracy.
{"title":"Machine Learning Approaches for Obsessive Compulsive Disorder Detection","authors":"Kabita Patel, Ajaya K. Tripathy","doi":"10.2478/ebtj-2023-0012","DOIUrl":"https://doi.org/10.2478/ebtj-2023-0012","url":null,"abstract":"Abstract Obsessive-Compulsive Disorder (OCD) is a psychiatric illness that produces significant psychological distress in patients. Individuals with OCD have recurring unwanted thoughts or sensations which make them obsessed with something and feel to do something repetitively as a compulsion. In general detection of OCD is performed by symptoms analysis. However, the symptoms are significantly visible at a later stage. Even individuals with OCD have less faith in the analysis of the symptoms as long as it is not affecting their life negatively. As a result, they start their treatment at a later stage and the treatment process becomes longer. However, it is observed that if the detection is performed through laboratory analysis through some biomarkers then the patients have more faith in the detection process and can start their treatment well in advance. Therefore laboratory detection of OCD can play a vital role in OCD treatment effectiveness. Most of the laboratory detection process proposed in the literature uses Machine Learning on related biomarkers. However, the prediction accuracy rate is not enough. This research aims to analyze the approaches to pediatric OCD based on machine learning using neuroimaging biomarkers and oxidative stress biomarkers. The challenges in OCD detection and prediction using neuroimaging biomarkers, oxidative stress biomarkers, and Machine Learning models have been described. Further, it analyzes the performance of different machine learning models that were used for OCD detection and highlights the research gap to improve prediction accuracy.","PeriodicalId":22379,"journal":{"name":"The EuroBiotech Journal","volume":"42 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135708016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Abstract The study has developed a model splicing construct assay system based on splicing misregulation, one of the major molecular features associated with myotonic dystrophy. The splicing construct assay has double reporters for intron 2 splicing in chloride channel (CLCN1). The CLCN1 transgene splicing construct assay was used to transfect wild type and DM fibroblast cell lines and the clones generated showed that it enabled quantification of splicing efficiency in transgene construct. Validation of the DM fibroblasts containing transgene splicing construct was performed by differentiating the DM fibroblasts into myoblasts which exhibited a switch in CLCN1 splicing construct which was consistent with that associated with myotonic dystrophy (DM) condition. The myoblast derived from fibroblasts cell-based gene-splicing assay was subsequently applied in therapeutic screening in small throughput screens of 113 compounds which identified Protein Kinase C inhibitors- hypericin and Ro-31-8220 as potential therapeutic agents. The CLCN1 gene-splicing assay is a good model system for application in therapeutic screening in myotonic dystrophy because its double reporters facilitated quantification of effect putative drug on correction of misregulated splicing.
{"title":"A Cell-Based Double Reporter Gene Splicing Assay for Therapeutic Screening in Myotonic Dystrophy","authors":"I. Udosen, J. Granados, J. Brook","doi":"10.2478/ebtj-2023-0011","DOIUrl":"https://doi.org/10.2478/ebtj-2023-0011","url":null,"abstract":"Abstract The study has developed a model splicing construct assay system based on splicing misregulation, one of the major molecular features associated with myotonic dystrophy. The splicing construct assay has double reporters for intron 2 splicing in chloride channel (CLCN1). The CLCN1 transgene splicing construct assay was used to transfect wild type and DM fibroblast cell lines and the clones generated showed that it enabled quantification of splicing efficiency in transgene construct. Validation of the DM fibroblasts containing transgene splicing construct was performed by differentiating the DM fibroblasts into myoblasts which exhibited a switch in CLCN1 splicing construct which was consistent with that associated with myotonic dystrophy (DM) condition. The myoblast derived from fibroblasts cell-based gene-splicing assay was subsequently applied in therapeutic screening in small throughput screens of 113 compounds which identified Protein Kinase C inhibitors- hypericin and Ro-31-8220 as potential therapeutic agents. The CLCN1 gene-splicing assay is a good model system for application in therapeutic screening in myotonic dystrophy because its double reporters facilitated quantification of effect putative drug on correction of misregulated splicing.","PeriodicalId":22379,"journal":{"name":"The EuroBiotech Journal","volume":"7 1","pages":"155 - 164"},"PeriodicalIF":1.7,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48008108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Suparerk Oonchit, B. Cherdhirunkorn, P. Tharabenjasin, N. Pabalan, Kumpol Chintanavilas, Robert S Marks, Yardnapar Parcharoen, C. Pechyen
Abstract This study aimed to modify screen-printed carbon micro-electrode surfaces by coating them with multiwall carbon-based nanotubes conjugated with chitosan and then validated the formed multiwall carbon-based nanotubes-chitosan coated screen printed carbon micro-electrode for the detection of homocysteine, a biomarker analyte known as a risk indicator in cardiovascular disease. The microstructure surface and crystallographic structure stability of the formed multiwall carbon-based nanotubes-chitosan obtained at formed multiwall carbon-based nanotubes per chitosan ratios of 1:1, 2:1, 3:1, and 4:1 were examined via field emission scanning electron microscopy, X-ray radiation, Raman spectroscopy, surface area and pore size, and thermogravimetric analyses. Homocysteine solutions at 30–100 µM were measured by cyclic voltammetry using the different formed multiwall carbon-based nanotubes-chitosan compositions as sensor electrodes. That with an optimal formed multiwall carbon-based nanotubes per chitosan ratio of 4:1 showed the highest crystallinity and electrical conductivity and gave a high coefficient of determination (R2 = 0.9036) between the homocysteine concentration and the oxidation current detection over an operating range of 30–100 µM. This new composite microelectrode for detecting homocysteine concentration makes it a promising candidate for clinical applications.
{"title":"Electrode surfaces based on multiwall carbon nanotubes-chitosan composites validated in the detection of homocysteine biomarkers for cardiovascular disease risk monitoring","authors":"Suparerk Oonchit, B. Cherdhirunkorn, P. Tharabenjasin, N. Pabalan, Kumpol Chintanavilas, Robert S Marks, Yardnapar Parcharoen, C. Pechyen","doi":"10.2478/ebtj-2023-0010","DOIUrl":"https://doi.org/10.2478/ebtj-2023-0010","url":null,"abstract":"Abstract This study aimed to modify screen-printed carbon micro-electrode surfaces by coating them with multiwall carbon-based nanotubes conjugated with chitosan and then validated the formed multiwall carbon-based nanotubes-chitosan coated screen printed carbon micro-electrode for the detection of homocysteine, a biomarker analyte known as a risk indicator in cardiovascular disease. The microstructure surface and crystallographic structure stability of the formed multiwall carbon-based nanotubes-chitosan obtained at formed multiwall carbon-based nanotubes per chitosan ratios of 1:1, 2:1, 3:1, and 4:1 were examined via field emission scanning electron microscopy, X-ray radiation, Raman spectroscopy, surface area and pore size, and thermogravimetric analyses. Homocysteine solutions at 30–100 µM were measured by cyclic voltammetry using the different formed multiwall carbon-based nanotubes-chitosan compositions as sensor electrodes. That with an optimal formed multiwall carbon-based nanotubes per chitosan ratio of 4:1 showed the highest crystallinity and electrical conductivity and gave a high coefficient of determination (R2 = 0.9036) between the homocysteine concentration and the oxidation current detection over an operating range of 30–100 µM. This new composite microelectrode for detecting homocysteine concentration makes it a promising candidate for clinical applications.","PeriodicalId":22379,"journal":{"name":"The EuroBiotech Journal","volume":"7 1","pages":"144 - 154"},"PeriodicalIF":1.7,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47943351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：